Literature DB >> 10529654

Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: influence of L-NAME and aspirin.

S K Tsai1, C H Huang, S S Huang, L M Hung, C Y Hong.   

Abstract

This study was designed to evaluate the in vivo effect of magnolol and honokiol on the acute phase of coronary ligation in the presence of nitric oxide inhibitor (L-NAME) or cyclooxygenase inhibitor (aspirin). After Sprague-Dawley rats were anesthetized with urethane, the changes of ventricular arrhythmia induced by coronary ligation for 30 min were determined with or without pretreatment with study medications. The incidence and duration of ventricular arrhythmia were significantly reduced after intravenous pretreatment (15 min before coronary ligation) with 10(-7) g/kg magnolol or 10(-7) g/kg honokiol. However, the antiarrhythmic effect of magnolol or honokiol could be abolished with the pretreatment of 1 mg/kg L-NAME, but not with pretreatment of 100 mg/kg aspirin. The abolishment of the myocardial beneficial effect of magnolol and honokiol by L-NAME, instead of aspirin, suggests an involvement of an increased nitric oxide synthesis in the protection offered by magnolol and honokiol against arrhythmia during myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529654     DOI: 10.1159/000028324

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  19 in total

1.  Stimulation of the BK(Ca) channel in cultured smooth muscle cells of human trachea by magnolol.

Authors:  S-N Wu; C-C Chen; H-F Li; Y-K Lo; S-A Chen; H-T Chiang
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Inhibitory Effects of Honokiol on the Voltage-Gated Potassium Channels in Freshly Isolated Mouse Dorsal Root Ganglion Neurons.

Authors:  Anqi Sheng; Yan Zhang; Guang Li; Guangqin Zhang
Journal:  Neurochem Res       Date:  2017-11-24       Impact factor: 3.996

3.  Role of nitric oxide in regulating cardiac electrophysiology.

Authors:  L Wang
Journal:  Exp Clin Cardiol       Date:  2001

Review 4.  Dietary lignans: physiology and potential for cardiovascular disease risk reduction.

Authors:  Julia Peterson; Johanna Dwyer; Herman Adlercreutz; Augustin Scalbert; Paul Jacques; Marjorie L McCullough
Journal:  Nutr Rev       Date:  2010-10       Impact factor: 7.110

5.  Dual Specific Phosphatase 7 Exacerbates Dilated Cardiomyopathy, Heart Failure, and Cardiac Death by Inactivating the ERK1/2 Signaling Pathway.

Authors:  Jing Liu; Yihen Yin; Jing Ni; Peiyu Zhang; Wei-Ming Li; Zheng Liu
Journal:  J Cardiovasc Transl Res       Date:  2022-05-20       Impact factor: 4.132

Review 6.  Honokiol: a novel natural agent for cancer prevention and therapy.

Authors:  S Arora; S Singh; G A Piazza; C M Contreras; J Panyam; A P Singh
Journal:  Curr Mol Med       Date:  2012-12       Impact factor: 2.222

7.  Honokiol inhibits tumor necrosis factor-α-stimulated rat aortic smooth muscle cell proliferation via caspase- and mitochondrial-dependent apoptosis.

Authors:  Shuli Fan; Xu Li; Jie Lin; Sijiao Chen; Jinhua Shan; Guoxian Qi
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

8.  Cardiovascular protection of magnolol: cell-type specificity and dose-related effects.

Authors:  Jennifer Hui-Chun Ho; Chuang-Ye Hong
Journal:  J Biomed Sci       Date:  2012-07-31       Impact factor: 8.410

9.  Magnolia polyphenols attenuate oxidative and inflammatory responses in neurons and microglial cells.

Authors:  Dennis Y Chuang; Ming-Huan Chan; Yijia Zong; Wenwen Sheng; Yan He; Jing Hua Jiang; Agnes Simonyi; Zezong Gu; Kevin L Fritsche; Jiankun Cui; James C Lee; William R Folk; Dennis B Lubahn; Albert Y Sun; Grace Y Sun
Journal:  J Neuroinflammation       Date:  2013-01-29       Impact factor: 8.322

10.  Honokiol protects rat hearts against myocardial ischemia reperfusion injury by reducing oxidative stress and inflammation.

Authors:  Yun Wang; Zhong-Ze Zhang; Yun Wu; Jia Zhan; Xiang-Hu He; Yan-Lin Wang
Journal:  Exp Ther Med       Date:  2012-10-25       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.